title: Diagnostic value of dynamic contrast-enhanced MRI in the salivary gland tumors.
abstract: To evaluate the diagnostic value of dynamic contrast-enhanced MRI (DCE-MRI) in salivary gland tumors, thirty-five patients (47 lesions) who underwent MR examinations and were histopathologically diagnosed with salivary gland tumors in Okayama University Hospital, between April 1998 and March 2005, were entered in the present study. The parameters included CI(max300) or CI(max600), which was the contrast index (CI) at maximal contrast enhancement upon 300 s or 600 s, and Tmax, which was the time that corresponded to the CI(max300). Washout ratio (WR(300) or WR(600)) was defined as follows: CI(max300)-CI(300s)/CI(max300) or CI(max600)-CI(600s)/CI(max600)x100 (%), where CI(300) or CI(600) was the CI at 300s or 600s after contrast medium administration. We obtained the following results from the analysis of DCE-MRI parameters; (a) The salivary gland tumors were categorized into three CI curve types according to Tmax and WR300; Pleomorphic adenoma; Tmax > 210 s and WR300 < 10%, Warthin tumor; Tmax < 60 s and WR300 > 40%, and malignant tumor; 60s < Tmax < 210 s and 10% < WR300 < 30%; (b) On the basis of the relationship between Tmax and CImax or WR, all pleomorphic adenomas were successfully differentiated from Warthin tumor lesions. Of the 20 pleomorphic adenomas, 18 (90.0%) were successfully differentiated from malignant tumors. All Warthin tumor lesions were successfully differentiated from pleomorphic adenomas and malignant tumors. Of 12 the malignant tumors, 11 (91.7%) were successfully differentiated from pleomorphic adenomas. All malignant tumors were successfully differentiated from Warthin tumors. Thus, DCE-MRI parameters are useful in diagnosing salivary gland tumors on the basis of the combined assessment of Tmax and CImax or WR.
authors.affiliation: Department of Oral and Maxillofacial Radiology, Field of Tumor Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-chome, Okayama 700-8525, Japan.
authors.forename: Miki
authors.initials: M
authors.lastname: Hisatomi
authors.forename: Jun-ichi
authors.initials: J
authors.lastname: Asaumi
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Yanagi
authors.forename: Teruhisa
authors.initials: T
authors.lastname: Unetsubo
authors.forename: Yuu
authors.initials: Y
authors.lastname: Maki
authors.forename: Jun
authors.initials: J
authors.lastname: Murakami
authors.forename: Hidenobu
authors.initials: H
authors.lastname: Matsuzaki
authors.forename: Yasutoshi
authors.initials: Y
authors.lastname: Honda
authors.forename: Hironobu
authors.initials: H
authors.lastname: Konouchi
mesh_terms: D000235:Adenolymphoma / Q000175:diagnosis; D008949:Adenoma, Pleomorphic / Q000175:diagnosis; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003937:Diagnosis, Differential; D005260:Female; D019786:Gadolinium DTPA; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008875:Middle Aged; D010307:Parotid Neoplasms / Q000175:diagnosis; D019275:Radiopharmaceuticals; D012468:Salivary Gland Neoplasms / Q000175:diagnosis*; D012680:Sensitivity and Specificity
chemical_list: D019275:Radiopharmaceuticals; D019786:Gadolinium DTPA